ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for default 登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。
BioAge Labs Inc

BioAge Labs Inc (BIOA)

5.33
0.19
(3.70%)
終了 1月22日 6:00AM
5.33
0.00
( 0.00% )
プレマーケット: 6:02PM

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

主要統計と詳細

通貨
5.33
買値
4.75
売値
5.58
出来高
-
0.00 日の範囲 0.00
3.85 52 週間の範囲 26.62
時価総額
前日終値
5.33
始値
-
時刻
最終取引時間
-
財務取引量
-
VWAP
-
平均取引量 (3 か月)
789,910
発行済株式数
35,848,738
配当利回り
-
PER
-2.99
1 株当たり利益 (EPS)
-1.78
歳入
-
純利益
-63.85M

BioAge Labs Inc について

BioAge Labs is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Our technology platform and differentiated human datasets enable us to identify promising targets based on insights in... BioAge Labs is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Our technology platform and differentiated human datasets enable us to identify promising targets based on insights into molecular changes that drive aging. Azelaprag, our lead product candidate, demonstrated the ability to more than double the weight loss induced by a glucagon-like-peptide-1 receptor (GLP-1R) agonist while also restoring healthy body composition and improving muscle function in preclinical obesity models. These preclinical results are supported by our Phase 1b clinical trial in older adults on bed rest where we observed decreased muscle atrophy, preservation of muscle quality and improved metabolism in subjects treated with azelaprag over a 10-day period. 詳細を表示

セクター
Pharmaceutical Preparations
業界
Pharmaceutical Preparations
ウェブサイト
本社
Newark, Delaware, USA
設立
-
BioAge Labs Inc is listed in the Pharmaceutical Preparations sector of the ナスダック市場 with ticker BIOA. The last closing price for BioAge Labs was US$5.33. Over the last year, BioAge Labs shares have traded in a share price range of US$ 3.85 to US$ 26.62.

BioAge Labs currently has 35,848,738 shares in issue. The market capitalisation of BioAge Labs is US$191.07 million. BioAge Labs has a price to earnings ratio (PE ratio) of -2.99.

BIOA 最新ニュース

The Gross Law Firm Reminds BioAge Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - BIOA

The Gross Law Firm Reminds BioAge Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - BIOA PR Newswire NEW YORK, Jan. 20, 2025 NEW YORK, Jan. 20, 2025...

BioAge Labs, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before March 10, 2025 to Discuss Your Rights - BIOA

BioAge Labs, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before March 10, 2025 to Discuss Your Rights - BIOA PR Newswire NEW YORK, Jan. 16, 2025 NEW YORK, Jan. 16, 2025...

BioAge Labs, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before March 10, 2025 to Discuss Your Rights - BIOA

BioAge Labs, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before March 10, 2025 to Discuss Your Rights - BIOA PR Newswire NEW YORK, Jan. 13, 2025 NEW YORK, Jan...

Class Action Filed Against BioAge Labs, Inc. (BIOA) - March 10, 2025 Deadline to Join - Contact The Gross Law Firm

Class Action Filed Against BioAge Labs, Inc. (BIOA) - March 10, 2025 Deadline to Join - Contact The Gross Law Firm PR Newswire NEW YORK, Jan. 9, 2025 NEW YORK, Jan. 9, 2025 /PRNewswire/ -- The...

BIOA INVESTOR ALERT: Edelson Lechtzin LLP Urges BioAge Labs, Inc. (NASDAQ: BIOA) Shareholders to Consult Legal Counsel About the Impending Lead Plaintiff Deadline in the Securities Fraud Class Action

BIOA INVESTOR ALERT: Edelson Lechtzin LLP Urges BioAge Labs, Inc. (NASDAQ: BIOA) Shareholders to Consult Legal Counsel About the Impending Lead Plaintiff Deadline in the Securities Fraud Class...

BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions

Collaboration will leverage BioAge's differentiated human longevity data and platform and Novartis expertise in the biology of physical exercise to identify drug targets to treat diseases related...

BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of Obesity

Decision follows observations of liver transaminitis without clinically significant symptoms in some subjects on azelaprag Company will evaluate data from patients enrolled to date and share...

BioAge Labs to Present at Goldman Sachs “Year-Ahead” Catalyst Clinic

RICHMOND, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for...

BioAge Labs to Present at Upcoming Investor Conferences

RICHMOND, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for...

BioAge Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates

Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesity Completed $238.3 million initial public offering and concurrent private placement, cash and cash...

期間 †前日比前日比 %始値高値安値平均出来高VWAP
10.6313.40425531914.75.384.42931195.05930562CS
4-0.67-11.166666666766.474.44071765.34793095CS
12-19.47-78.508064516124.825.33.857899107.3280678CS
26-17.17-76.311111111122.526.623.8569771910.35626766CS
52-17.17-76.311111111122.526.623.8569771910.35626766CS
156-17.17-76.311111111122.526.623.8569771910.35626766CS
260-17.17-76.311111111122.526.623.8569771910.35626766CS

BIOA - Frequently Asked Questions (FAQ)

What is the current BioAge Labs share price?
The current share price of BioAge Labs is US$ 5.33
How many BioAge Labs shares are in issue?
BioAge Labs has 35,848,738 shares in issue
What is the market cap of BioAge Labs?
The market capitalisation of BioAge Labs is USD 191.07M
What is the 1 year trading range for BioAge Labs share price?
BioAge Labs has traded in the range of US$ 3.85 to US$ 26.62 during the past year
What is the PE ratio of BioAge Labs?
The price to earnings ratio of BioAge Labs is -2.99
What is the reporting currency for BioAge Labs?
BioAge Labs reports financial results in USD
What is the latest annual profit for BioAge Labs?
The latest annual profit of BioAge Labs is USD -63.85M
What is the registered address of BioAge Labs?
The registered address for BioAge Labs is 131 CONTINENTAL DRIVE, SUITE 301, NEW CASTLE, NEWARK, DELAWARE, 19713
What is the BioAge Labs website address?
The website address for BioAge Labs is www.bioagelabs.com
Which industry sector does BioAge Labs operate in?
BioAge Labs operates in the PHARMACEUTICAL PREPARATIONS sector

ムーバー

すべて表示
  • 出来高
  • 値上がり率
  • 値下がり率
銘柄コード株価出来高
CDIOCardio Diagnostics Holdings Inc
US$ 0.931
(53.13%)
4.46M
NEHCNew Era Helium Inc
US$ 4.06
(48.18%)
799.27k
IPAImmunoPrecise Antibodies Ltd
US$ 0.708
(43.61%)
825.34k
ASSTAsset Entities Inc
US$ 1.28
(42.22%)
3.33M
ADAGAdagene Inc
US$ 2.50
(41.08%)
1
TMCITreace Medical Concepts Inc
US$ 7.23
(-22.01%)
6
ELVNEnliven Therapeutics Inc
US$ 17.21
(-21.77%)
1
STFSStar Fashion Culture Holdings Ltd
US$ 10.90
(-19.32%)
3.03k
XENEXenon Pharmaceuticals Inc
US$ 31.51
(-19.16%)
4
LSTALisata Therapeutics Inc
US$ 3.18
(-18.46%)
22
CDIOCardio Diagnostics Holdings Inc
US$ 0.931
(53.13%)
4.46M
RIMEAlgorhythm Holdings Inc
US$ 0.0376
(8.67%)
3.39M
ASSTAsset Entities Inc
US$ 1.28
(42.22%)
3.33M
SHViShares Short Treasury Bond ETF
US$ 110.36
(0.00%)
1.8M
GCTKGlucoTrack Inc
US$ 0.1197
(-4.24%)
1.44M

最近閲覧した銘柄

Delayed Upgrade Clock